# LDL Cholesterol Reduction Following Ezetimibe Initiation

Study · id `cardio:ct-nct07839741` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07839741](<https://clinicaltrials.gov/study/NCT07839741>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07839741

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT07839741. Allocation not applicable; no masking; primary purpose treatment. Start 2025-06-01 (actual); primary completion 2027-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT07839741, source copy `cardio:ctgov-nct07839741-2026-09-24`, retrieved 2026-10-31)
- Started: 2025-06-01 (actual) (ClinicalTrials.gov record NCT07839741, source copy `cardio:ctgov-nct07839741-2026-09-24`, retrieved 2026-10-31)
- Primary completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07839741, source copy `cardio:ctgov-nct07839741-2026-09-24`, retrieved 2026-10-31)
- Completion: 2027-04 (anticipated) (ClinicalTrials.gov record NCT07839741, source copy `cardio:ctgov-nct07839741-2026-09-24`, retrieved 2026-10-31)
- Countries: Portugal (ClinicalTrials.gov record NCT07839741, source copy `cardio:ctgov-nct07839741-2026-09-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07839741-2026-09-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: LDL Cholesterol Reduction Following Ezetimibe Initiation
- Acronym: EZE-TRACK
- Condition: Atherosclerotic Cardiovascular Disease (ASCVD)
- Condition: Cardiovascular Risk
- Condition: LDL Cholesterol
- Intervention (Drug): Ezetimibe
- Lead sponsor: Universidade do Porto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Universidade do Porto (`cardio:org-universidade-do-porto`)

## Provenance

Content hash: f7e2051c4e539d7635e5c8925dc880fd39c54d3f1c4128ecdfa8a3d5280e739e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
